Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual.
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year
Presentation of study design for potentially.